The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

3 months ago

Version History

Version 33 months ago

What changed: Updated with finalized pricing details for Intellia Therapeutics, reflecting a higher capital raise of $180 million compared to the initial $150 million estimate.

Version 23 months ago

What changed: Updated Oruka's offering size to $700.4 million, confirmed the $72.50 share price, and included specific underwriter share options.

Version 13 months ago

What changed: Updated the story to include Oruka Therapeutics' significantly larger $500 million offering and the inclusion of pre-funded warrants.

StocksUpdated×3•Originally published 27 April 2026•Updated 29 April 2026•

1 min read

Biotech Sector Sees Major Offerings Led by Oruka and Intellia

Key Facts

1Intellia Therapeutics has commenced an underwritten public offering of $150 million of shares of its common stock.

2Intellia intends to grant underwriters a 30-day option to purchase up to an additional 15% of the shares offered.

The biotechnology sector is witnessing a surge in capital raising, highlighted by Oruka Therapeutics upsizing its public offering to approximately $700.4 million at $72.50 per share. In a parallel development, Intellia Therapeutics finalized its public offering pricing at $10.75 per share for 16,744,187 shares of common stock. Gross proceeds for Intellia are now expected to reach approximately $180 million, exceeding the initial $150 million estimate due to strong demand. Additionally, Intellia granted underwriters a 30-day option to purchase up to 2,511,628 additional shares. These concurrent capital raises underscore a broader trend of biotech firms fortifying balance sheets to fund expensive clinical pipelines. Market participants are closely monitoring how this influx of liquidity will accelerate research in CRISPR-based therapies and genomic medicine.

Sources:

globenewswire.com